Oral testosterone undecanoate shows promising results for first use in the real world


“We were surprised to see that the majority of subjects in these simulations had testosterone levels within eugonadal range for all 3 dose's studies,” says Jay Newmark, MD, MBA.

In this video, Jay Newmark, MD, MBA, discusses the background, findings, and takeaways of the study, “Real-World Experience with First FDA-Approved Oral Testosterone Undecanoate Formulation,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Newmark is a chief medical officer at Clarus Therapeutics, Northbrook, Illinois.

Related Videos
Roger R. Dmochowski, MD, MMHC, FACS, answers a question during a Zoom video interview
Smita De, MD, PhD, answers a question during a Zoom video interview
© 2023 MJH Life Sciences

All rights reserved.